Overview

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Synthekine
Treatments:
Cyclophosphamide
Fludarabine